Tarsus Pharmaceuticals, Inc. (TARS)

NASDAQ: TARS · IEX Real-Time Price · USD
36.89
-0.06 (-0.16%)
Mar 4, 2024, 4:00 PM EST - Market closed
-0.16%
Market Cap 1.28B
Revenue (ttm) 17.45M
Net Income (ttm) -135.89M
Shares Out 34.22M
EPS (ttm) -4.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 865,782
Open 37.74
Previous Close 36.95
Day's Range 36.33 - 38.22
52-Week Range 11.33 - 40.40
Beta 1.07
Analysts Strong Buy
Price Target 49.00 (+32.83%)
Earnings Date Feb 27, 2024

About TARS

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to ad... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 16, 2020
Employees 244
Stock Exchange NASDAQ
Ticker Symbol TARS
Full Company Profile

Financial Performance

In 2023, TARS's revenue was $17.45 million, a decrease of -32.42% compared to the previous year's $25.82 million. Losses were -$135.89 million, 118.9% more than in 2022.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for TARS stock is "Strong Buy." The 12-month stock price forecast is $49.0, which is an increase of 32.83% from the latest price.

Price Target
$49.0
(32.83% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Tarsus Announces Pricing of $100.0 Million Public Offering

IRVINE, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new te...

3 days ago - GlobeNewsWire

Tarsus Announces Proposed $100.0 Million Public Offering

IRVINE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new tec...

4 days ago - GlobeNewsWire

Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements

Launched XDEMVY ® (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis and generated fourth quarter net product sales of $13.1 million, and $14.7 million in the first four m...

6 days ago - GlobeNewsWire

Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease

TP-05 demonstrated tolerability and statistically significant tick mortality, suggesting potential for on-demand Lyme disease prophylaxis TP-05 demonstrated tolerability and statistically significant ...

11 days ago - GlobeNewsWire

Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024

IRVINE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tre...

13 days ago - GlobeNewsWire

Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference

IRVINE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tre...

4 weeks ago - GlobeNewsWire

Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites

TP-03 demonstrated statistically significant and clinically meaningful improvements across two objective measures of MGD, regardless of BID or TID dosing, and was well tolerated TP-03 demonstrated sta...

3 months ago - GlobeNewsWire

Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements

Launched XDEMVY ® (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis

4 months ago - GlobeNewsWire

Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023

IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tre...

4 months ago - GlobeNewsWire

Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis

IRVINE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tr...

6 months ago - GlobeNewsWire

Tarsus to Present at Upcoming Investor Conferences

IRVINE, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tre...

6 months ago - GlobeNewsWire

Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis

Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out of every 12 adults. XDEMVY is indicated for all adult patients with Demodex blepharitis and is available v...

6 months ago - GlobeNewsWire

Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements

XDEMVY™ (lotilaner ophthalmic solution) 0.25% received FDA approval for the treatment for Demodex blepharitis On track to have XDEMVY and sales force in market by the end of August 2023 Completed enro...

7 months ago - GlobeNewsWire

Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock

IRVINE, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new tec...

7 months ago - GlobeNewsWire

Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock

IRVINE, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new tec...

7 months ago - GlobeNewsWire

FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis

XDEMVY is the first and only approved therapeutic for Demodex blepharitis, a highly prevalent eyelid disease that impacts approximately 25 million eye care patients in the U.S.

7 months ago - GlobeNewsWire

Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis

IRVINE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tre...

9 months ago - GlobeNewsWire

Tarsus to Present at the Jefferies Global Healthcare Conference

IRVINE, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tre...

9 months ago - GlobeNewsWire

Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements

Continuing to build market awareness through disease education and deploying commercial leadership in anticipation of TP-03 August 25, 2023 PDUFA

10 months ago - GlobeNewsWire

Tarsus Launches “Don't Freak Out. Get Checked Out.

Demodex blepharitis is a highly prevalent, yet often undiagnosed eyelid disease that impacts approximately 25 million eye care patients in the U.S.

10 months ago - GlobeNewsWire

Tarsus to Participate at the Bank of America 2023 Healthcare Conference

IRVINE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize trea...

10 months ago - GlobeNewsWire

Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer

IRVINE, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tr...

11 months ago - GlobeNewsWire

Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements

Engaging with more than two-thirds of key optometrists and/or ophthalmologists, and top payers on Demodex blepharitis in anticipation of TP-03 August 25, 2023 PDUFA

1 year ago - GlobeNewsWire

Tarsus Added to NASDAQ Biotechnology Index

IRVINE, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tre...

1 year ago - GlobeNewsWire

Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease

Positive Phase 1b Callisto data shows that TP-05 is well tolerated and safety data supports progression to Phase 2a

1 year ago - GlobeNewsWire